At a glance
ClinicalIndex Comparison RecordN/ACompleted· 12 enrolled
Drug / intervention
lyophilized blueberry supplementdietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Blueberry Supplementation on Alzheimer's Biomarkers
In Brief
A clinical study evaluating lyophilized blueberry supplement for Mild Cognitive Impairment and Alzheimer Disease. Completed, enrolled 12 participants across 1 site.
Detailed Summary
The purpose of this study is to study the effects of blueberries on neuronal, glial, and pathology blood biomarkers in Mild Cognitive Impairment (MCI) and to estimate sample size for future confirmatory studies. The blood biomarkers to be measured are Neurofilament light (NfL), glial fibrillary acidic protein (GFAP), Aß40, Aß42, p-tau181, and cytokines, using an ultra-sensitive state-of-the-art immunoassay.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMild Cognitive Impairment, Alzheimer Disease
CountriesUnited States
CollaboratorsU.S. Highbush Blueberry Council
Timeline
N/ACompletedFinished
20222023202420252026
First PostedDec 2021
Enrollment StartFeb 2022
Primary CompletionFeb 2023
TodayJul 2026
First PostedDec 29, 2021
Enrollment StartFeb 21, 2022
Primary CompletionFeb 6, 2023
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 4.5 years ago
Interventions
lyophilized blueberry supplementdietary
lyophilized blueberry supplement bid